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Recognition of nonkeratinizing morphology in oropharyngeal squamous cell carcinoma – a
prospective cohort and interobserver variability study
Aims: Nonkeratinizing morphology in oropharyngeal
squamous cell carcinoma (NKSCC) strongly correlates
with human papillomavirus and p16 status, but as a
unique diagnostic entity is not widely recognized by
pathologists. We sought to prospectively examine the
performance of a new histological typing system during
1 year of routine clinical practice (Aim 1) and also its
reproducibility amongst six head and neck pathologists
using a 40 case test set (Aim 2).
Methods and Results: The three histological types
were: Type 1 (keratinizing), Type 2 (nonkeratinizing
with maturation) and Type 3 (nonkeratinizing). For
Aim 1, there were 85 cases. p16 immunohistochem-
istry was positive in five of the 18 (27.8%) cases
classified as Type 1, 18 of the 19 (94.7%) as Type 2,
and 47 of the 48 (97.9%) as Type 3. For Aim 2,
agreement among pathologists on the test cases was
best for types 1 and 3 (kappa values 0.62 and 0.56;
P < 0.0001) and lowest for type 2 (kappa 0.35;
P < 0.0001). All 21 cases classified as NK SCC (type
3) by any of the reviewers was p16 positive.
Conclusions: Pathologists can recognize NK SCC with
good agreement, and when a pathologist classifies a
tumour as NK SCC, this reliably predicts p16 positivity.
Keywords: morphology, nonkeratinizing, oropharyngeal, p16, squamous cell carcinoma
Introduction
Oropharyngeal squamous cell carcinoma (SCC) is now
recognized as distinct because of its strong association
with high risk human papillomavirus (HPV).1,2 Con-
ventional head and neck SCC is strongly associated with
smoking, smokeless tobacco use, and ⁄ or heavy alcohol
use while HPV-related oropharyngeal SCC is associated
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with higher numbers of sex partners and higher oral sex
exposure.3 Conventional head and neck SCC commonly
occurs in middle aged to older men without a significant
race predilection, while HPV-related oropharyngeal SCC
occurs in slightly younger patients, is even more
common in men than women, is associated with lower
smoke exposure, and is more common in Caucasians.4
While conventional head and neck SCC rates are
dropping, those for oropharyngeal SCC are increasing
so that oropharyngeal SCC is accounting for a larger
percentage of all head and neck SCC.2,5,6
HPV-related oropharyngeal SCC is biologically dis-
tinct as well. The tumours are less genetically complex,7
less frequently harbour p53 mutations,8,9 and show
differing global gene expression profiles compared to
HPV-negative oropharyngeal SCC.7 HPV-related oropha-
ryngeal SCC is characterized by transcriptionally-active
virus with the E6 and E7 transcripts altering cell cycle
functions and apoptosis. E6 binds to wild type tumour
suppressor protein p53 through E6 associated protein,
and E7 binds to retinoblastoma (Rb) protein, each
leading to their degradation.10 Rb degradation results
in aberrant overexpression of the tumour suppressor
protein p1611–15 because Rb normally inhibits p16
transcription.5 This high level p16 expression in HPV-
related carcinoma is in contrast to conventional head
and neck SCC where the gene is frequently inactivated by
methylation or deletion.16 As such, p16 is a very good
surrogate marker for HPV-related oropharyngeal SCC,5
and it is easily detected by immunohistochemistry.
From a large amount of retrospective,15,17 and now
prospective data,11,14,18,19 clinical outcomes have been
shown to be markedly better for HPV-related oropha-
ryngeal SCC despite their tendency to present with
nodal metastases. The tumours are more treatment
responsive but have also been shown to do better
regardless of primary treatment modality, whether
surgical or non-surgical.15,19,20 Patients also have
lower rates of second primary tumours.21
While virtually all major types of head and neck SCC,
by subsite or variation, have been defined by histopath-
ologic features, this has not been the case with oropha-
ryngeal SCC. Rather, the tumours have been identified
by HPV presence and ⁄ or clinical and molecular
changes. While it has been consistently noted that the
HPV-related oropharyngeal SCC cases usually have
characteristic morphologic features,22,23 many pathol-
ogists are still unfamiliar with them. The majority of
these tumours have a ‘‘blue cell’’ appearance which has
variably been described as ‘poorly differentiated’, ‘basal’,
or ‘basaloid’.23–25 In fact, terminology amongst pathol-
ogists for oropharyngeal SCC has been extremely vari-
able. And the guidance in classification has been
variable. For example, the 2005 WHO classification of
oral cavity and oropharynx tumours reports that for
SCC, ‘findings in the oral cavity and oropharynx do not
differ significantly from those of the larynx and hypo-
pharynx.’ It goes on to further recommend that tumours
be graded simply into well-, moderately-, and poorly
differentiated categories but then state that ‘grading by
differentiation is really of limited prognostic value.’26
There is no discussion of the specific morphologic
features that we now know are unique in the orophar-
ynx. Also, in our experience, oropharyngeal SCC classi-
fication varies widely amongst practicing pathologists,
with widely varying terminology and with many com-
monly using the term basaloid, which is used for a distinct
histological variant of SCC, thus generating confusion
with the common patterns of oropharyngeal SCC.
HPV-related oropharyngeal SCCs tend to be submu-
cosal and lobulated with large, well-circumscribed and
smooth-edged nests of cells with little stromal reaction.
The cells have indistinct cell borders, small to modest
amounts of eosinophilic cytoplasm, and oval to spindled
nuclei which are hyperchromatic and lack (or have
inconspicuous) nucleoli. There is brisk mitotic activity
and abundant apoptosis. Comedo-type necrosis is also
common. Maturing squamous differentiation is typi-
cally focal or absent. This morphologic appearance has
also been characterized as ‘nonkeratinizing’27 and the
distinction clearly made between this morphologic
tumour type and that of conventional head and neck
SCC which is usually ‘keratinizing’ with irregular,
stellate nests of tumour cells with abundant eosinophilic
cytoplasm, oval nuclei with frequent nucleoli, and brisk
stromal desmoplasia (Figures 1, 2, and 3).28
We previously developed a histological typing system
for oropharyngeal SCC and have shown the nonkera-
tinizing histological types to strongly correlate with
HPV and p16 positivity and to predict for improved
patient outcomes independent of all other clinical,
pathologic, and treatment variables.12,28
In this study, we sought to assess the reproducibility
of this histological typing system amongst head and
neck pathologists naive to the system. We also sought
to assess the relationship of the types to tumour p16
status in a prospective manner on routine clinical cases
of oropharyngeal SCC.
Materials and methods
histological typing
A histological typing system for oropharyngeal SCC
consisting of three types, as previously published,12,28
was utilized for this study.
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keratiniz ing scc (k scc or type 1)
This tumour type consists entirely (or diffusely) of
maturing squamous epithelium with no areas with NK
SCC or ‘basal’ morphology (Figure 1). The cells have
polygonal shapes with abundant, eosinophilic (kerati-
nizing) cytoplasm, distinct cell borders, and intercellu-
lar bridges. The nests are usually angulated and
irregular, and there is frequently marked stromal
desmoplasia. Actual keratin formation is common but
is not required as long as the cells have prominent
eosinophilic cytoplasm along with the other features.
This cytoplasm is filled with keratin intermediate
filaments so despite sometimes lacking frank keratin
formation, the cells still are ‘keratinizing’. These
tumours can range from well to poorly differentiated.
nonkeratiniz ing scc (nk scc or type 3)
This tumour type consists of sheets, nests, or trabeculae
of oval and frequently spindled, hyperchromatic cells
with indistinct cell borders and lacking prominent
nucleoli (Figure 2). They have very little or only
modest amounts of eosinophilic cytoplasm. Comedo-
type necrosis and brisk mitotic activity are usually
present. There is typically no (or minimal) stromal
reaction to the invading tumour. Portions of the
tumour can show squamous maturation, characterized
by polygonal cells with mature, eosinophilic cytoplasm,
distinct cell borders, intercellular bridges, and keratin
pearls, but these mature areas should constitute <10%
of the total surface area.
nonkeratiniz ing scc with maturation
( ‘hybrid scc’ or type 2)
This tumour type has features seen in both of the other
two types, consisting of definitive areas with NK SCC
morphology but also having maturing squamous
differentiation comprising >10% of tumour surface
area (Figure 3). These ‘maturing areas’ have cells with
Figure 1. Typical histological features of a keratinizing-type (Type 1)
SCC with angulated nests of tumour cells which have abundant,
eosinophilic cytoplasm, well-defined cell borders, and round nuclei
with vesicular chromatin and occasional prominent nucleoli. There is
also marked stromal desmoplasia (H&E; 100· magnification; SCC,
squamous cell carcinoma).
Figure 2. Typical histological features of a nonkeratinizing (Type 3)
SCC with well-circumscribed nests of tumour cells having round to
oval, hyperchromatic nuclei, minimal cytoplasm, and abundant
apoptosis and mitotic activity (H&E; 200· magnification; SCC,
squamous cell carcinoma).
NK
K
Figure 3. Typical histological features of a nonkeratinizing SCC with
maturation (Type 2) with large, smooth bordered nests of tumour
cells, some of which have nonkeratinizing features (NK) with others
having keratinizing-type maturation (K) with abundant eosinophilic
cytoplasm. There is a focus of reverse maturation (arrow), and the
tumour nests show ‘clefting’ artifact with separation from the stroma.
Both of these latter features are common in Type 2 tumours (H&E;
200· magnification; SCC, squamous cell carcinoma).
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more abundant, eosinophilic cytoplasm, nuclei with
open chromatin and ⁄ or prominent nucleoli, irregular,
angulated nests with stromal desmoplasia, or areas of
frank keratinization. They also frequently show ‘re-
verse maturation’, where the basal appearing cells are
central in the nests but the cells at the periphery show
squamous maturation. This is the opposite maturation
pattern than what is seen in typical keratinizing type
head and neck SCC.
Other rare histological types such as basaloid, spindle
cell, undifferentiated, and adenosquamous carcinoma
were diagnosed based on their published features,29–33
and were excluded. Basaloid SCC is frequently confused
with nonkeratinizing SCC although, in our view, it is
histologically distinct. It was specifically defined based
on Wain’s description29 of the histological features and
based on the presence of rounded rather than spindled
tumours cells, ‘jigsaw puzzle’ pattern nesting with
molding of the nests to one another leaving thin lines of
intervening stroma, central mucoid material in the
nests, and hyalinized, basement membrane-like, peri-
cellular stroma.
study aim 1
Aim 1 of this study was an evaluation of the
histological typing system in prospective, routine,
clinical practice. We prospectively captured one con-
secutive year of data (1 ⁄ 1 ⁄ 2010 to 1 ⁄ 1 ⁄ 2011) on in
house oropharyngeal SCC cases at Washington Uni-
versity ⁄ Barnes Jewish Hospital. All cases were assigned
a histological type utilizing our system by one of the
three Washington University head and neck patholo-
gists (JSL, RDC, SKE) simply depending on who was
covering the head and neck surgical pathology service
during the year and prior to any ancillary testing.
During this time, we had also instituted a policy of
performing p16 immunohistochemistry (methods be-
low) on all new primary oropharyngeal SCC cases. We
captured these immunohistochemical results on all
patients and correlated them with the histological
types. None of the cases represented recurrent disease,
and none had undergone prior therapy.
study aim 2
Aim 2 of this study was an evaluation of the interob-
server variation for the histologic typing in oropharyn-
geal SCC cases. We utilized a preexisting research
database of 270 patients with oropharyngeal SCC
which was established from clinical databases from the
departments of Radiation Oncology and Otolaryngol-
ogy Head and Neck Surgery at Washington University.
The cases in this database were from 1997 to 2008,
and 75% were from primary surgical resections.
Corresponding blocks and slides had been retrieved
from the files of the Barnes Jewish Hospital. Hematox-
ylin and eosin (H&E) slides had been previously
reviewed by one of the authors (JSL) without knowl-
edge of clinical follow up or outcome, and the tumours
categorized using the previously described histological
typing system. For the current study, we randomly
A B C
Figure 4. Representative p16 immunohistochemistry in the three histological tumour types A) No staining for p16 in keratinizing SCC
(Type 1) B) Strong and diffuse p16 positivity in nonkeratinizing SCC with maturation (Type 2) C) Strong and diffuse p16 positivity in
nonkeratinizing SCC (Type 3) (SCC, squamous cell carcinoma).
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selected 40 cases from this larger group to generate a
study set. To reflect the frequency of each histological
type in the larger database (which was 25% each for
Types 1 and 2 and 50% for Type 3), we randomly
selected 10 cases each of Types 1 and 2 and 20 of Type
3 to arrive at the total of 40. We picked representative
blocks, generated 4 lm hematoxylin and eosin sec-
tions, and randomly labelled them one through 40. We
also selected representative examples of each of the
three histological types, generated single hematoxylin
and eosin slides from them, and labelled them as typical
examples of Types 1, 2, and 3 for the reviewers to view
prior to categorizing the unknown cases. A single page
description of the three histological types and their
typical features was provided to the reviewers (Data
S1). The study set was then circulated for review to six
head and neck pathologists previously unfamiliar with
the specifics of the histological typing system (MP,
MBG, BPO, NSA, SM, and JBM), and their answers
collected and collated. The handout and example slides
were the only exchanged information between the
central pathologists and the external study reviewers
regarding tumour morphology and classification.
immunohistochemistry
Immunohistochemistry was performed for p16 on all
database cases and all prospective clinical cases. This
was performed on representative 4 lm sections cut
from formalin-fixed, paraffin-embedded tissue blocks
using a monoclonal antibody to p16 (MTM Laborato-
ries; monoclonal; 1:1 dilution) on a Ventana Bench-
mark LT automated immunostainer (Ventana Medical
Systems Inc., Tucson, AZ, USA) according to standard
protocols. Detection involved Ventana’s ultraView Uni-
versal DAB Detection Kit that utilizes a cocktail of
enzyme labelled secondary antibodies that locate the
bound primary antibody. The complex is then visual-
ized with a hydrogen peroxide substrate and a 3,3¢-
diaminobenzidine tetrahydrochloride (DAB) chromo-
gen. No biotin is involved. Antigen retrieval, standard
on the machine, utilized the Ventana CC1, EDTA-Tris,
pH 8.0 solution. A known p16 expressing head and
neck SCC case was used as the positive control and
sections of normal tonsil used for negative controls with
each run. Staining was nuclear and cytoplasmic in
all cases and was graded in a quartile manner for its
extent as follows: 0 = negative; 1 = 1–25% of cells
positive; 2+ = 26–50%; 3+ = 51–75%; 4+ = 76–
100% (Figure 4). Although partial p16 expression is
quite uncommon (approximately 5% of oropharyngeal
SCC),12 there is a growing consensus amongst head and
neck pathologists that only extensive p16 expression in
oropharyngeal SCC is associated with transcriptionally
active (and thus biologically and clinically significant)
HPV. For example, in the largest retrospective study on
oropharyngeal SCC and prognosis, the definition for a
positive p16 immunohistochemistry result was set at
>70% tumour staining.11 In addition, Schlecht et al., in
a recent publication, showed that strong p16 expression
is more consistently associated with high risk HPV E6
and E7 mRNA by RT-PCR.34 For this reason, we divided
our cases binarily into positive (3+ or 4+ or more
simply stated, >50% tumour cell staining) and negative
(0, 1+, or 2+ or more simply stated, no tumour cell
staining or <50% staining) groups.
statistics
When examining associations between two categorical
variables, for instance, p16 status and histological type,
we used Pearson’s Chi Square Test. In order to assess
agreements among multiple reviewers, a macro code
called ‘MAGREE’ from SAS Institute Company was
executed. The script is created by SAS for computing
estimates and tests of agreement among multiple
reviewers when responses (classifications or typings)
are on a nominal or ordinal scale. We reported kappa
and P values for agreement evaluations. All tests were
two sided, and the level for statistical significance was
set at <0.05. SAS 9.1 was used for all major statistical
calculations (SAS Institute Inc, Cary, NC, USA).
Results
study aim 1
Aim 1 consisted of 1 year of prospective oropharyngeal
SCC cases in routine clinical practice. There were a
Table 1. Aim 1 results showing p16 expression by tumour
histological type
Type Total cases p16 positivity*
Keratinizing (1) 18 5 (27.8%)
Nonkeratinizing with
maturation (2)
19 18 (94.7%)
Nonkeratinizing (3) 48 47 (97.9%)
85 70 (82.4%)
*The difference in p16 positivity rates amongst the three
histological types was statistically significant (P = 0.005). The
difference in p16 positivity rates for type 1 versus Types 2
and 3 combined was also statistically significant (P = 0.001).
[Correction added after online publication, 17 January 2012:
p16 positivity percentage amended for Keratinizing (1)].
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total of 85 new cases of oropharyngeal SCC over this
period, and data are presented in Table 1. Strong p16
expression was present in 70 of the 85 (82.4%) cases
(Figure 4). Interestingly, nonkeratinizing SCC strongly
predicted p16 status with 47 of 48 (97.9%) being
strongly p16 positive. The vast majority of nonkerati-
nizing SCC with maturation were also p16 positive
(18 ⁄ 19 or 94.7%) as were a significant minority of the
keratinizing SCC (5 ⁄ 18 or 27.8%). The differences in
p16 positivity rates between the three histological types
and also for type 1 versus types 2 and 3 (combined)
were statistically significant (P = 0.05 and 0.01,
respectively.
As previously mentioned, partial p16 expression is
uncommon in oropharyngeal SCC.12 For this Aim 1
cohort of 85 patients, 68 of the 70 (97.1%) p16
positive cases were 4+ and two of the 70 (2.9%) were
3+. Of the 15 p16 negative cases, 13 (86.7%) were
completely negative, and 2 (13.3%) were focally
positive, each showing <25% of the tumour staining.
These latter two cases were both keratinizing SCC
(Type 1).
study aim 2
Aim 2 consisted of a 40 case test set of oropharyngeal
SCC circulated to six external head and neck pathol-
ogists to evaluate agreement in histological typing. The
results for each case by reviewer are presented in
Table 2. All six reviewers agreed on 14 cases (35.0%),
at least five of six reviewers agreed on 25 cases
(62.5%), and at least four of six agreed on 30 cases
(75.0%). Kappa values for each histological type were
as follows: Type 1, 0.62 (P < 0.0001), Type 2, 0.35
(P < 0.0001), and Type 3, 0.56 (P < 0.0001). For
Types 1 and 3, these kappa values are generally
considered to be ‘moderate’ or ‘good’ to ‘substantial’
agreement, and for Type 2, the kappa value is generally
considered ‘fair’ or ‘poor’ agreement.35,36 Thirty three
of the 40 study set cases (82.5%) were p16 positive.
Correlation with p16 immunohistochemistry showed
that all 21 cases that were classified as Type 3
(nonkeratinizing SCC) by any reviewer were p16
positive.
Discussion
The importance of HPV as a causative agent in
oropharyngeal SCC has been emerging over the past
several decades of investigation.37 Transcriptionally
active HPV-related oropharyngeal SCCs present in
clinically distinct ways, are genetically less complex,
respond very well to treatment regardless of modality
used, and have a favourable prognosis.19 Testing for
HPV in such tumours is complicated, with myriad
different testing types such as DNA-based PCR, RNA-
based RT-PCR, DNA-based in situ hybridization, and
more recently, slide-based RNA in situ hybridization.30
The sensitivities of these assays for transcriptionally
active HPV vary considerably. p16 has been exten-
sively documented as a surrogate marker of trans-
criptionally active HPV in oropharyngeal SCC.
Overexpression of p16 has been consistently and
repeatedly shown to be associated with better response
to therapy and favourable clinical outcome in oro-
pharyngeal SCC.11–14,38,39 It is widely available, easy
to perform, and easy to interpret with staining either
being strongly and diffusely positive (with cytoplas-
mic and nuclear staining) or completely absent.
Traditionally in pathology and medicine, the micro-
scopic features of tumours have been used as the
basis for their classification. Nasopharyngeal carci-
noma is a perfect example, where the morphology is
utilized quite well to define subsets for association
with Epstein-Barr virus, clinical behaviour, treatment,
and prognostication. However, morphology not been
widely used for HPV-related SCC of the oropharynx.
Investigators have variably observed and reported
that HPV-related tumours are ‘poorly differentiated’
or have ‘basal’ or ‘basaloid’ features, frequently
lacking keratinization and having cells with only
small amounts of cytoplasm giving the tumours a
‘blue-cell’ appearance.18,23–25 Terminology and
descriptions have varied quite a bit, but more
recently the term ‘nonkeratinizing’12,22,28 has been
utilized in describing their appearance, and this term
appears to be gaining more widespread acceptance.
We previously developed a histological typing system
for routine oropharyngeal SCC cases consisting of three
types: Type 1 (or keratinizing-type SCC), Type 2 (or
nonkeratinizing SCC with maturation – representing
an intermediate or ‘mixed’ category), and Type 3 (or
nonkeratinizing SCC). We showed that the types
strongly correlate with tumour HPV and p16 status
and strongly predict patient outcomes.12,28 At Wash-
ington University in St Louis, we have been applying
this typing system for the reporting of active clinical
cases for several years. What had not been studied was
the performance of this typing system for routine
patient care nor the reproducibility of the system
amongst other head and neck pathologists.
In Aim 1 (routine surgical pathology practice eval-
uation) of this study, we have validated the use of our
histological typing system in routine practice. Virtually
all Type 2 (94.7%) and Type 3 (97.9%) cases were
strongly p16 positive by immunohistochemistry com-
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pared to 27.8% for Type 1, showing that nonkerati-
nizing morphology is an excellent surrogate marker for
strong p16 expression and, by extension, biologically
and clinically relevant HPV in the tumours.
In Aim 2 (interobserver variability evaluation) of this
study, we have shown that external pathologists,
provided only with simple descriptions of the morpho-
logic types, can identify nonkeratinizing and keratiniz-
ing-type squamous cell carcinomas. However, the
agreement was lower for nonkeratinizing SCC with
maturation (Type 2). This latter histological type is one
which has definitive nonkeratinizing histological fea-
tures, but which has more than 10% of the tumour
surface area showing squamous maturation, with cells
with abundant, eosinophilic cytoplasm, angulated nest
borders with stromal reaction, or keratinization. As an
intermediate group, it is perhaps not entirely surprising
that it had less agreement.
The significance and meaning of kappa values for
data is difficult to classify and is dependent on many
factors.34,35 Statistical significance (P values < 0.05), as
was reached for the interobserver agreement for all three
histological types in our study, is not a particularly good
guideline for considering the practical significance of the
Table 2. Aim 2 results showing reviewer typing results for
each case
Table 2. (Continued)
Green highlighting indicates 100% agreement, yellow high-
lighting indicates agreement by five of six (83.3%), and
orange highlighting indicates agreement by four of six
(66.6%). Rows with no highlighting indicate <66.6%
agreement. For p16 immunohistochemistry, all positive cases
showed expression in >75% of the cells and all negative
cases showed no expression in the tumour cells.
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agreement rates. Landis and Koch proposed descriptive
terms for ranges of kappa values (based on personal
opinion) such that <0 indicates no agreement and 0–
0.20 as slight, 0.21–0.40 as fair, 0.41–0.60 as moder-
ate, 0.61–0.80 as substantial, and 0.81–1 as almost
perfect agreement.34 However, this is dependent on so
many factors that a ‘good’ kappa value is very hard to
assign. The higher the number of variables tested, given
the same basic agreement levels, will give higher kappa
values. In our case, having only three variables ⁄ types,
and having kappas of 0.62 and 0.56 for keratinizing-
type and nonkeratinizing SCC, respectively, would
probably be considered relatively good agreement.
Why there is not higher agreement among the
reviewers in histological typing of such tumours is not
clear. The histological features of carcinomas, although
they can be described generally, are not always
consistent even within specific diagnostic types ⁄ cate-
gories. Variation amongst tumours within the three
types certainly may explain the significant number of
discrepant cases. Also, there is probably a tendency to
‘err’ on the side of putting tumours in the Type 2
category because it is intermediate between the two.
Indeed, of the 26 study set cases that had discrepant
typing by the reviewers, there were a total of 156
‘typings’, of which 35 (or 23%) were called Type 1, 46
(or 30%) were called Type 3, and 74 (or 47%) were
called Type 2. This overrepresentation of Type 2
amongst the discrepant cases argues that reviewers
‘fell back’ on Type 2 frequently in their typing. Our
personal experience with utilizing this typing system in
routine practice is that we become more confident with
calling Types 1 and 3 with more experience.
The larger question in the current management of
patients with oropharyngeal SCC is ‘where does histo-
logical typing potentially factor in?’ As risk stratifica-
tion factors for patients with oropharyngeal SCC have
become more clearly defined, routine HPV-specific
testing has been recommended and instituted by many.
However, p16 is a very good surrogate marker for HPV
and is arguably a better single predictor of good
outcome than any HPV-specific test. It strongly corre-
lates with the presence of transcriptionally active
HPV40 and consistently demonstrates equal or higher
risk stratification between positive and negative
cases.11,12,38,40 p16 immunohistochemistry is now
utilized as the single risk stratification test in oropha-
ryngeal SCC at many institutions. Nonkeratinizing
morphology, with its very strong association with the
presence of transcriptionally-active HPV, with p16
overexpression, and with improved patient outcomes, is
also helpful in identifying HPV-related tumours. In our
previous large oropharyngeal SCC study cohort,12 124
of 126 (98.4%) nonkeratinizing SCC (Type 3) cases
were strongly p16 positive. In Aim 1 of the current
study, 47 of 48 (97.9%) SCC cases that were classified
as nonkeratinizing were p16 positive, and in Aim 2, all
21 of the cases from the study set that any of the
reviewers classified as nonkeratinizing SCC were p16
positive. Based on this data, nonkeratinizing histology
essentially implies p16 positivity. One could then
reasonably propose that oropharyngeal SCC can be
typed by the pathologist at the time of diagnosis, and if
the tumour is Type 3, p16 testing could be omitted
because positive staining is essentially assured. If the
tumour is Type 1 or 2, p16 immunohistochemistry
should be performed and reported. Although Type 2
tumours in our prospective (Aim 1) cohort were almost
all p16 positive (95%), this is an intermediate histo-
logical category that overlaps with keratinizing-type
(Type 1) tumours. We saw in the interobserver cohort
(Aim 2) that many cases were variably classified as
Type 1 and 2 by the various observers so p16
immunohistochemistry would still be indicated.
In smaller medical facilities or poor countries, where
ancillary studies like p16 immunohistochemistry or
HPV-specific testing might be difficult or impossible to
obtain, pathologists can use nonkeratinizing histo-
logical features to still help predict which patients have
better prognosis tumours. Nonkeratinizing histological
features can also be very helpful in practice, otherwise.
For example, in neck metastases (which are a common
presentation specimen for oropharyngeal SCC because
the primary tumours are frequently clinically occult),
recognizing the nonkeratinizing (Type 3) or even
nonkeratinizing with maturation (Type 2) morphology
at frozen section can help one guide the surgeons to the
oropharynx (or less commonly the nasopharynx) as the
likely primary site. This morphology should prompt one
to consider HPV as causative in such tumours and, if
indicated, to do p16 immunohistochemistry or HPV-
specific testing. And since WHO Type 2a (or differen-
tiated nonkeratinizing) nasopharyngeal carcinoma can
be histologically somewhat similar to oropharyngeal
nonkeratinizing SCC, Epstein-Barr virus staining
should also be considered, particularly if p16 immu-
nohistochemistry or HPV-specific testing is negative.
Finally, our results add further credence to the idea
that, as currently defined and utilized, grading and
differentiation are not clinically useful in oropharyn-
geal SCC.41 The terms ‘poorly differentiated’,13,23 ‘high
grade’, and ‘basaloid’,18,24 which are frequently
applied to nonkeratinizing SCC in the literature and
in clinical practice, imply (just as in almost every other
organ system and tumour type) a more aggressive
tumour with a poorer prognosis for the patient.
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However, this is the exact opposite of the case for
oropharyngeal SCC, where the most ‘poorly differenti-
ated’ looking tumours do exceptionally well clinically
with the appropriate treatment.18 The most well-
differentiated, mature keratinizing type SCCs are usu-
ally unrelated to HPV, present with larger primary
tumours, and have worse prognosis.12,25,28 We have
carefully avoided the term ‘grade’ in our study and in
our proposed terminology for this very reason.
Pure basaloid SCC of the head and neck, a tumour
type which occurs in the larynx, hypopharynx, and
oropharynx and is frequently clinically aggressive, has
some morphologic features which overlap nonkerati-
nizing SCC. Basaloid and nonkeratinizing SCC are
frequently confused with each other. In the practice of
seeing many ‘blue’ looking oropharyngeal SCC cases
over the years, however, we have found that basaloid
SCC and nonkeratinizing SCC, when clearly defined,
are distinct. And, importantly, oropharyngeal basaloid
SCC is a mixed variant with the HPV-related tumours
having more favourable outcomes. We have been
careful to exclude cases of true basaloid SCC from our
study by strictly defining them with the histological
features that are well-described in the literature.29,42,43
In summary, we have further validated a three-tiered
histological typing system in oropharyngeal SCC.
Nonkeratinizing histological morphology can be rec-
ognized by pathologists, can be utilized for diagnosis in
routine practice, and correlates almost perfectly with
strong p16 expression by immunohistochemistry. Our
hope is that this well-characterized typing system for
oropharyngeal SCC will help to eliminate some of the
confusion about these tumours.
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